We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Neurocognitive Function in Patients with Major Depressive Disorder during Duloxetine Treatment.
- Authors
Yasuhiro Kaneda
- Abstract
Objective: Patients with major depressive disorder (MDD) have been reported to perform less well in neurocognitive tests than normal control subjects. The author investigated the effects of duloxetine on cognitive function, namely processing speed in patients with MDD. Methods: In this longitudinal, observational study, the subjects consisted of 31 adult outpatients receiving duloxetine as antidepressant therapy. The assessments were performed using the Zung Self-Rating Depression Scale (SDS) for the severity of depression, and the Symbol Coding Task (SCT) for evaluation of processing speed. Results: 1) At one month, six of the 22 patients exhibited full remission. At two months, nine of the 18 patients exhibited full remission. At three months, eight of the 13 patients exhibited full remission. 2) Significantly decreased SDS scores were observed during the 3-month study period, while SCT scores increased significantly. Conclusions: Antidepressant therapy with duloxetine improved both depression and processing speed assessed by the SCT.
- Subjects
BRAIN physiology; COGNITION disorders diagnosis; DIAGNOSIS of mental depression; ANALYSIS of variance; MENTAL depression; LONGITUDINAL method; MEDICAL needs assessment; NEUROLOGICAL disorders; T-test (Statistics); DISEASE remission; DATA analysis software; DULOXETINE; THERAPEUTICS
- Publication
International Medical Journal, 2017, Vol 24, Issue 2, p177
- ISSN
1341-2051
- Publication type
Article